US · Healthcare · Drug Manufacturers - General
EPS came in at 0.19 against a street estimate of 0.27 — a miss of 29.6%.
Analysts rate Grifols SA ADR a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $10.87.
| Fund | Stake |
|---|---|
| Brandes Investment Partners & Co | 5.56% |
| Capital World Investors | 3.37% |
| Permian Investment Partners | 2.90% |
| Black Creek Investment Management Inc | 1.23% |
| Millennium Management LLC | 0.64% |
| Bank of America Corp | 0.64% |
| HHG PLC | 0.48% |
| UBS Group AG | 0.46% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.09 / share ex-date Jul 2, 2026 · pay Jul 9, 2026 | 2026-07-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Grifols SA ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.